Prognostic value of miR-26a and HMGA1 in urothelial bladder cancer

Biomedicine and Pharmacotherapy

Volumn 68, Issue 8, 2014, Pages 929-934

  Lin, Rongkai ^a   Shen, Wenhao ^a   Zhi, Yi ^a   Zhou, Zhansong ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

High mobility group AT hook 1; MicroRNA 26a; Prognosis; Tumor progression; Urothelial bladder cancer

Indexed keywords

HIGH MOBILITY GROUP A1A PROTEIN; MICRORNA; MIRN26A MICRORNA, HUMAN; TUMOR MARKER;

ADULT; AGED; BIOSYNTHESIS; FEMALE; GENE EXPRESSION REGULATION; HUMAN; MALE; METABOLISM; MIDDLE AGED; PROGNOSIS; URINARY BLADDER NEOPLASMS;

ADULT; AGED; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGA1A PROTEIN; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84916228866     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.10.003     Document Type: Article

References (30)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J Clin 2012, 62:10-29.
2. Ghoneim M.A., Abdel-Latif M., el-Mekresh M., Abol-Enein H., Mosbah A., Ashamallah A. Radical cystectomy for carcinoma of the bladder: 2720 consecutive cases 5 years later. J Urol 2008, 180:121-127.
3. Netto G.J. Molecular genetics and genomics progress in urothelial bladder cancer. Semin Diagn Pathol 2013, 30:313-320.
4. Skeldon S.C., Larry Goldenberg S. Bladder cancer: a portal into men's health. Urol Oncol 2014, [In press].
5. DeSouza K., Chowdhury S., Hughes S. Prompt diagnosis key in bladder cancer. Practitioner 2014, 258:23-27. [3].
6. Rosser C.J., Urquidi V., Goodison S. Urinary biomarkers of bladder cancer: an update and future perspectives. Biomark Med 2013, 7:779-790.
7. Huang J.T., Wang J., Srivastava V., Sen S., Liu S.M. MicroRNA machinery genes as novel biomarkers for cancer. Front Oncol 2014, 4:113.
8. http://www.mirbase.org/.
9. Palanichamy J.K., Rao D.S. miRNA dysregulation in cancer: towards a mechanistic understanding. Front Genet 2014, 5:54.
10. Stahlhut C., Slack F.J. MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications. Genome Med 2013, 5:111.
11. Walther W., Schlag P.M. Current status of gene therapy for cancer. Curr Opin Oncol 2013, 25:659-664.
12. Yoshino H1, Seki N., Itesako T., Chiyomaru T., Nakagawa M., Enokida H. Aberrant expression of microRNAs in bladder cancer. Nat Rev Urol 2013, 10:396-404.
13. Zabolotneva AA1, Zhavoronkov A.A., Shegay P.V., Gaifullin N.M., Alekseev B.Y., Roumiantsev S.A., et al. A systematic experimental evaluation of microRNA markers of human bladder cancer. Front Genet 2013, 4:247.
14. Ratert N1, Meyer H.A., Jung M., Lioudmer P., Mollenkopf H.J., Wagner I., et al. miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. J Mol Diagn 2013, 15:695-705.
15. Guo P., Nie Q., Lan J., Ge J., Qiu Y., Mao Q. C-Myc negatively controls the tumor suppressor PTEN by upregulating miR-26a in glioblastoma multiforme cells. Biochem Biophys Res Commun 2013, 441:186-190.
16. Jiang D.S., Wang Y.W., Jiang J., Li S.M., Liang S.Z., Fang H.Y. MicroRNA-26a involved in Toll-like receptor 9-mediated lung cancer growth and migration. Int J Mol Med 2014, 34:307-312.
17. Shen W., Song M., Liu J., Qiu G., Li T., Hu Y., et al. MiR-26a promotes ovarian cancer proliferation and tumorigenesis. PLoS ONE 2014, 9:e86871.
18. Zhou H., Guo W., Zhao Y., Wang Y., Zha R., Ding J., et al. MicroRNA-26a acts as a tumor suppressor inhibiting gallbladder cancer cell proliferation by directly targeting HMGA2. Int J Oncol 2014, 44:2050-2058.
19. Song Q.C., Shi Z.B., Zhang Y.T., Ji L., Wang K.Z., Duan D.P., et al. Downregulation of microRNA-26a is associated with metastatic potential and the poor prognosis of osteosarcoma patients. Oncol Rep 2014, 31:1263-1270.
20. Deng J., He M., Chen L., Chen C., Zheng J., Cai Z. The loss of miR-26a-mediated post-transcriptional regulation of cyclin E2 in pancreatic cancer cell proliferation and decreased patient survival. PLoS ONE 2013, 8:e76450.
21. Lin Y., Chen H., Hu Z., Mao Y., Xu X., Zhu Y., et al. miR-26a inhibits proliferation and motility in bladder cancer by targeting HMGA1. FEBS Lett 2013, 587:2467-2473.
22. Edge S.B., Byrd D.R., Compton C.C., Fritz A.G., Greene F.L., Trotti A. AJCC cancer staging manual 2010, Springer, New York.
23. Eble J.N., Sauter G., Epstein J.I., Sesterhenn I.A. World Health Organization Classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organ 2004, IARC Press, Lyon.
24. Resar L.M. The high mobility group A1 gene: transforming inflammatory signals into cancer?. Cancer Res 2010, 70:436-439.
25. Aiello A., Pandini G., Sarfstein R., Werner H., Manfioletti G., Vigneri R., et al. HMGA1 protein is a positive regulator of the insulin-like growth factor-I receptor gene. Eur J Cancer 2010, 46:1919-1926.
26. Eilebrecht S., Brysbaert G., Wegert T., Urlaub H., Benecke B.J., Benecke A. 7SK small nuclear RNA directly affects HMGA1 function in transcription regulation. Nucleic Acids Res 2011, 39:2057-2072.
27. Takeuchi I., Takaha N., Nakamura T., Hongo F., Mikami K., Kamoi K., et al. High mobility group protein AT-hook 1 (HMGA1) is associated with the development of androgen independence in prostate cancer cells. Prostate 2012, 72:1124-1132.
28. Belton A., Gabrovsky A., Bae Y.K., Reeves R., Iacobuzio-Donahue C., Huso D.L., et al. HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells. PLoS ONE 2012, 7:e30034.
29. Piscuoglio S., Zlobec I., Pallante P., Sepe R., Esposito F., Zimmermann A., et al. HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph node metastasis in pancreatic adenocarcinoma. Histopathology 2012, 60:397-404.
30. Massimi I., Guerrieri F., Petroni M., Veschi V., Truffa S., Screpanti I., et al. The HMGA1 protoncogene frequently deregulated in cancer is a transcriptional target of E2F1. Mol Carcinog 2013, 52:526-534.